Image Source: Zacks Investment Research iDose TR’s Clinical Success: The 36-Month Follow-Up Data Recent findings from a 36-month follow-up analysis of two Phase 3 pivotal trials underscore iDose ...

The firm says its “bullish” key opinion leader checks indicated the “disruptive potential” of iDose across the U.S. glaucoma treatment landscape over the next several years. The checks ...

Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year ...

The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose ...

Strong growth in the US glaucoma franchise with record fourth-quarter net sales of $56.3 million, driven by the success of iDose TR. The company faces potential headwinds from foreign currency ...

Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three ...

Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...